[go: up one dir, main page]

MX2020005565A - Proceso para la preparacion de compuestos enlazantes de farmaco. - Google Patents

Proceso para la preparacion de compuestos enlazantes de farmaco.

Info

Publication number
MX2020005565A
MX2020005565A MX2020005565A MX2020005565A MX2020005565A MX 2020005565 A MX2020005565 A MX 2020005565A MX 2020005565 A MX2020005565 A MX 2020005565A MX 2020005565 A MX2020005565 A MX 2020005565A MX 2020005565 A MX2020005565 A MX 2020005565A
Authority
MX
Mexico
Prior art keywords
binding compounds
preparation
drug binding
drug
compounds
Prior art date
Application number
MX2020005565A
Other languages
English (en)
Inventor
Sophie Blanchard
James Coats
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2020005565A publication Critical patent/MX2020005565A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La descripción se relaciona de manera general con procesos novedosos para la preparación de compuestos enlazantes de fármaco y composiciones que comprenden esos compuestos enlazantes de fármaco.
MX2020005565A 2017-11-30 2018-11-29 Proceso para la preparacion de compuestos enlazantes de farmaco. MX2020005565A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593104P 2017-11-30 2017-11-30
PCT/US2018/063070 WO2019108797A1 (en) 2017-11-30 2018-11-29 Process for the preparation of drug linker compounds

Publications (1)

Publication Number Publication Date
MX2020005565A true MX2020005565A (es) 2020-08-20

Family

ID=66665808

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005565A MX2020005565A (es) 2017-11-30 2018-11-29 Proceso para la preparacion de compuestos enlazantes de farmaco.
MX2023009372A MX2023009372A (es) 2017-11-30 2020-07-13 Proceso para la preparacion de compuestos enlazantes de farmaco.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009372A MX2023009372A (es) 2017-11-30 2020-07-13 Proceso para la preparacion de compuestos enlazantes de farmaco.

Country Status (15)

Country Link
US (2) US11612666B2 (es)
EP (1) EP3717016A4 (es)
JP (2) JP7402159B2 (es)
KR (2) KR102762352B1 (es)
CN (2) CN111417408B (es)
AU (1) AU2018375412B2 (es)
BR (1) BR112020010503A2 (es)
CA (1) CA3082165A1 (es)
EA (1) EA202091340A1 (es)
IL (1) IL274757B1 (es)
MA (1) MA51870A (es)
MX (2) MX2020005565A (es)
SG (1) SG11202004698RA (es)
WO (1) WO2019108797A1 (es)
ZA (1) ZA202003037B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745738C1 (ru) * 2019-05-20 2021-03-31 МэбПлекс Интернэшнл Ко., Лтд. Однореакторный способ получения промежуточного продукта конъюгата антитело-лекарственное средство
EP3838913A4 (en) * 2019-10-23 2021-11-03 MabPlex International Co., Ltd. OLIGOPEPTIDE LINKER INTERMEDIATE AND MANUFACTURING PROCESS FOR IT
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
PT2489364E (pt) * 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
AU2006290567A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A Comb polymers
CA2662981A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
WO2009002427A2 (en) * 2007-06-21 2008-12-31 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
EP2714684B1 (en) * 2011-05-27 2018-09-05 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
CN104662000B (zh) * 2012-05-15 2018-08-17 索伦托医疗有限公司 药物偶联物及其偶联方法和用途
HRP20180859T1 (hr) * 2012-12-07 2018-07-13 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
US9533483B2 (en) 2014-09-26 2017-01-03 Kimberly-Clark Worldwide, Inc. Apparatus for and method of shaping and applying a segment to a moving web

Also Published As

Publication number Publication date
US20200360532A1 (en) 2020-11-19
AU2018375412B2 (en) 2025-01-02
BR112020010503A2 (pt) 2020-10-20
US20240042052A1 (en) 2024-02-08
EA202091340A1 (ru) 2020-10-16
KR102762352B1 (ko) 2025-02-05
WO2019108797A1 (en) 2019-06-06
JP2023164652A (ja) 2023-11-10
US11612666B2 (en) 2023-03-28
MX2023009372A (es) 2023-08-16
KR20250024092A (ko) 2025-02-18
EP3717016A4 (en) 2021-09-01
MA51870A (fr) 2020-10-07
ZA202003037B (en) 2023-12-20
CN111417408B (zh) 2024-04-23
IL274757A (en) 2020-07-30
SG11202004698RA (en) 2020-06-29
CA3082165A1 (en) 2019-06-06
KR20200094185A (ko) 2020-08-06
JP7787859B2 (ja) 2025-12-17
AU2018375412A1 (en) 2020-05-28
JP2021505542A (ja) 2021-02-18
CN118271394A (zh) 2024-07-02
EP3717016A1 (en) 2020-10-07
CN111417408A (zh) 2020-07-14
JP7402159B2 (ja) 2023-12-20
IL274757B1 (en) 2025-12-01

Similar Documents

Publication Publication Date Title
SA519401180B1 (ar) مركبات بيروليزين بها استبدال واستخداماتها
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
CO2018004124A2 (es) Compuestos heterocíclicos
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12020550703A1 (en) Sulfonamide compounds and use thereof
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
PH12019550235A1 (en) Kinase inhibitors and uses thereof
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
MX391538B (es) Proceso de compuesto antifungico.
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX378847B (es) Nuevos derivados de gamma-amanitina
MX384427B (es) Composiciones de proteína concentrada y métodos para su elaboración y uso.
MX2020006283A (es) Proceso para la preparación de opicapona y sus intermediarios.
BR112016028037A2 (pt) Novos compostos
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
HK1257296A1 (zh) 新的化合物及其用途
MX2020005565A (es) Proceso para la preparacion de compuestos enlazantes de farmaco.
MX2020000873A (es) Derivados de ácidos biliares marcados isotópicamente.
EA201790321A1 (ru) Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações